about
Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data.Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinomaA randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG).Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for responseCharacterization of rare transforming KRAS mutations in sporadic colorectal cancer.Cure of pulmonary Rhizomucor pusillus infection in a patient with hairy-cell leukemia: role of liposomal amphotericin B and GM-CSF.Colorectal cancer in Chinese patients: current and emerging treatment options.An update on the pharmacodynamics, pharmacokinetics, safety and clinical efficacy of nivolumab in the treatment of solid cancers.Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutationsClinical significance of CDX2-positive circulating tumour cells in colorectal cancer patients.Isolated tumor cells and circulating CK20 mRNA in pN0 colorectal cancer patients.Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus.Radiotherapy for nasopharyngeal carcinoma--transition from two-dimensional to three-dimensional methods.Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma.Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions.Update on the management and therapeutic monitoring of advanced nasopharyngeal cancer.Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumorsUpdate in antiepidermal growth factor receptor therapy in the management of metastatic colorectal cancer.Population-based differences in treatment outcome following anticancer drug therapies.Current and future molecular diagnostics in colorectal cancer and colorectal adenoma.Novel systemic therapeutic for nasopharyngeal carcinoma.Management of hepatocellular carcinoma: beyond sorafenib.Personalizing therapy for colorectal cancer.Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization.Advanced technologies for studying circulating tumor cells at the protein level.An update on the safety and efficacy of regorafenib in the treatment of solid cancers.Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079).The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group.Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective.Investigational drugs for nasopharyngeal carcinoma.Jagged 2 silencing inhibits motility and invasiveness of colorectal cancer cell lines.Clinical outcome of neoadjuvant chemoradiation in locally advanced rectal cancer at a tertiary hospital.The metalloprotease ADAMTS8 displays antitumor properties through antagonizing EGFR-MEK-ERK signaling and is silenced in carcinomas by CpG methylation.Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models.Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma.Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study.Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines.Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.
P50
Q31152723-2CCE4A19-5C9C-4633-ACF5-ADDDB5FB7051Q33262273-0D3358C8-0B5E-4778-AA8B-1880152CFBD9Q33368982-4DFAFFF4-C73A-47A7-9DED-0B1ADDBE132BQ33371606-E5C5B275-B424-4BCD-995A-83896BC7ACD8Q33422744-2ACCA789-BE13-4F92-BD31-5E4B81638DBFQ33727871-165EB533-707A-492E-AEC2-8B423EDB4CF5Q34120234-55A54ECE-BA2A-4AFD-8A01-D4569B57DF04Q34352595-343E347F-5EAA-4C5B-8860-F513301C867AQ34538075-B19DFD05-EC72-4830-958C-44DCBE4D56FDQ34549536-4420B1E2-8928-46AC-A489-1EAC57B899EDQ34727224-B1BD8181-7192-4A7B-B611-7FD53E1B3637Q34767579-A8E9E7CF-4619-4170-8947-603E3A0BAC4FQ35246679-EAD1E6B8-7C9F-4342-9259-35984FF7DA14Q35948252-74618F6F-30BD-4CB5-B4DC-A38637A0437FQ36407458-CD42224D-2257-4D77-B2B3-711A08EF54B2Q37171008-BD1E966C-1304-4C2D-94BA-B19146182043Q37325872-58C534AF-85C5-4F0A-8F6C-94478F348B9AQ37375259-F7727CC9-463B-41DB-A393-E692702D2409Q37443898-93955496-096A-4A03-A842-744D29A81666Q37686610-EF1A447B-4765-4B92-BDE5-B3A6B4026F01Q37697538-EE5B63AD-1216-4486-9FB4-BC20538FA4EEQ37982126-95EBB5EC-00CE-490F-A6FC-91E3418B06CBQ37995523-3F9307E3-59D9-4254-8A73-F441EFF5D92CQ38136420-5E874F33-5371-4ADC-8902-72539F8AFCB6Q38152608-9844F80A-85CD-460C-B3C5-BF5DCFA9C859Q38160932-12C2AAA7-31B8-465A-A873-4FDE5A820A96Q38260324-DFF39D3A-DAC7-4D2D-BF5F-6776664A2884Q38385856-B1DE9078-D947-4EC5-BCFE-37248C8519B2Q38446683-21A2BB58-D10D-4AA9-AFE6-9A5D9620FBF6Q38583301-2B61D562-555E-4F0F-88E3-0125326CEFEFQ38690528-B73A8A8A-B3AF-4F5F-BB7E-2B3D28F59C75Q38768264-3E27BB45-EB90-4AA8-8DDC-C6A02BE6B58EQ38994422-DE5A4002-E084-4FAE-9EBE-D87260C7D99DQ39067669-CB578C73-2922-43B5-98D8-7FDF20C37E8AQ39095022-CF961A10-C68F-4D9A-982D-8B58A2000B8CQ39105272-5F44C706-F700-4EAC-B327-FAD9FC453F9AQ39172796-9662A857-C142-465D-AB29-EF759E181157Q39250247-244938F2-5980-481D-AB29-403C34CAF7FAQ39352296-0514C564-9963-43DF-84C4-45AC3247540BQ39704048-E2B11773-6F64-4749-8A93-3653B59E247E
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Brigette Ma
@ast
Brigette Ma
@en
Brigette Ma
@es
Brigette Ma
@nl
type
label
Brigette Ma
@ast
Brigette Ma
@en
Brigette Ma
@es
Brigette Ma
@nl
prefLabel
Brigette Ma
@ast
Brigette Ma
@en
Brigette Ma
@es
Brigette Ma
@nl
P106
P31
P496
0000-0003-4802-1102